Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Core Insights - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases [1] - The company will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with a webcast available for 90 days post-event [1] Company Overview - Q32 Bio targets potent regulators of the adaptive immune system to develop innovative therapies for alopecia areata and other autoimmune and inflammatory diseases [1] - Approximately 700,000 individuals in the U.S. are affected by alopecia areata, which significantly impacts their lives and has limited treatment options [1] Product Development - Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody, currently in a Phase 2 program for treating alopecia areata [1] - The IL-7 and TSLP pathways are implicated in various T cell-mediated autoimmune diseases, highlighting the potential of Q32 Bio's therapeutic approach [1]